Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon alpha therapy - Amarillo Biosciences/Xiamen Weiyang Pharmaceutical

Drug Profile

Interferon alpha therapy - Amarillo Biosciences/Xiamen Weiyang Pharmaceutical

Latest Information Update: 25 Feb 2020

At a glance

  • Originator Amarillo Biosciences
  • Developer Xiamen Weiyang Pharmaceutical
  • Class Interferons
  • Mechanism of Action Immunostimulants; Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research COVID 2019 infections

Most Recent Events

  • 13 Feb 2020 Early research in COVID-2019-infections in China (PO)

Development Overview

Introduction

Low-dose oral interferon alpha therapy is being developed by Xiamen Weiyang Pharmaceutical under a license agreement with Amarillo Biosciences for the treatment of COVID-2019 infections. The oral interferon product works indirectly by boosting the immune system, making the development of viral resistance highly unlikely. When interferon is given orally the interferon reaches the mucosa of the back of the throat where the interferon attaches to receptors and activates hundreds of interferon-sensitive genes that help the immune system respond to the viral infection. Early research is underway in China.

Company Agreements

In July 2019, Amarillo Biosciences announced that it entered into a into a Term Sheet outlining a licensing and royalty agreement with Xiamen Weiyang Pharmaceutical. Under the Term Sheet, Amarillo Biosciences proposes to license the right and responsibility to develop, manufacture and commercialize an IFNa related therapy to Xiamen Weiyang in China for the treatment of an undisclosed indication. In exchange, Amarillo Biosciences would receive an upfront license fee and cash or equity payments as per the achievement of specific milestones and a royalty based on gross revenues from the sale of the product in the China market. Xiamen Weiyang is to cross-license the future products, know-how, and technologies resulting from the venture for Amarillo Biosciences products and worldwide distribution outside of China to Amarillo Biosciences . [1]

Key Development Milestones

As of February 2020, low-dose oral interferon alpha therapy is in early stage development for the treatment of COVID-2019 infections [2] .

Patent Information

The interferon alpha therapy has six issued patents (five in U.S. and one in Taiwan) and a registered trademark, in the US. The sixth entitled "Treatment of Thrombocytopenia Using Orally Administered Interferon", was issued on July 21, 2017, and will expire in 2033 (Amarillo Biosciences website, February 2020).

Drug Properties & Chemical Synopsis

  • Route of administration PO
  • Formulation unspecified
  • Class Interferons
  • Target Interferon alpha
  • Mechanism of Action Immunostimulants; Interferon alpha stimulants
  • WHO ATC code

    J05 (Antivirals for Systemic Use)

  • EPhMRA code

    J5 (Antivirals for Systemic Use)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - - Research China PO / unspecified Xiamen Weiyang Pharmaceutical 13 Feb 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
Amarillo Biosciences Originator USA
Amarillo Biosciences Owner USA
Xiamen Weiyang Pharmaceutical Licensee China

Development History

Event Date Update Type Comment
13 Feb 2020 Phase Change Early research in COVID-2019-infections in China (PO) [2] Updated 25 Feb 2020
31 Jul 2019 Licensing Status Amarillo Biosciences enters into a Term Sheet outlining a licensing and royalty agreement with Xiamen Weiyang Pharmaceutical for interferon alpha therapy [1] Updated 25 Feb 2020
21 Jul 2017 Patent Information Amarillo Biosciences has patent protection for interferon alpha therapy in USA and Taiwan (Amarillo Biosciences website, February 2020) Updated 25 Feb 2020

References

  1. Amarillo Biosciences and Xiamen Weiyang Pharmaceutical Sign Term Sheet Outlining China Licensing and Royalty Agreement.

    Media Release
  2. Amarillo Biosciences to Explore Low-Dose Oral Interferon Therapeutics in China as a Line of Defense Against Coronavirus and Other Viral Indications.

    Media Release
Back to top